Exact Sciences Corp stock (US30063P1057): Nasdaq-listed cancer diagnostics group steady after recent gains

Exact Sciences shares traded little changed on Nasdaq on Friday after a strong rebound in recent months, as investors digest the latest quarterly figures and valuation metrics for the Madison-based cancer diagnostics specialist.

Exact Sciences shares were broadly stable in Friday trading on the Nasdaq, with the cancer diagnostics stock consolidating after a strong recovery over the past year from its 52-week low, as investors continue to weigh the group’s growth profile and valuation in the United States market, according to Nasdaq data as of late May 2026.

The stock, which is listed on Nasdaq under the ticker EXAS, has traded in a 52-week range of USD 38.81 to USD 104.98 and recently changed hands near the upper end of that band, with a market capitalization of about USD 20 billion, based on figures reported by MarketBeat as of late May 2026.

For German investors, the shares are also available on trading venues such as Tradegate via secondary listings, typically quoted in euro and tracking the primary Nasdaq price in US dollars, although liquidity remains centered in the United States.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Exact Sciences Corp
• Sector/industry: Molecular diagnostics / biotechnology focused on cancer screening
• Headquarters/country: Madison, United States
• Core markets: United States, with growing presence in international colorectal cancer screening and oncology testing markets
• Key revenue drivers: Cologuard stool DNA colorectal cancer screening test, precision oncology assays and related diagnostic services
• Home exchange/listing venue: Nasdaq (EXAS)
• Trading currency: USD

Exact Sciences Corp: core business model

Exact Sciences focuses on molecular diagnostics for early cancer detection and monitoring, with revenues primarily generated from its Cologuard screening test and a portfolio of precision oncology assays used by physicians and healthcare systems in key markets such as the United States.

Valuation metrics and multiples for Exact Sciences Corp

With a market capitalization around USD 20.0 billion and the share price close to its 52-week high, Exact Sciences is trading at levels that reflect strong growth expectations but also a valuation premium relative to many traditional healthcare names, according to MarketBeat data as of late May 2026.

MarketBeat reports that the stock currently does not show a conventional trailing price-earnings ratio because the group has focused on reinvesting in growth and innovation rather than generating consistent net profit, while the consensus analyst price target of about USD 92 suggests that Wall Street views the stock more through the lens of revenue expansion, margin progression and cash-flow inflection than through near-term earnings multiples.

Investors in the United States often supplement headline valuation metrics with enterprise-value-to-sales and long-term margin assumptions for diagnostic and biotechnology peers when assessing Exact Sciences, given the company’s emphasis on scaling test volumes, expanding guideline inclusion and broadening reimbursement coverage for its cancer screening and precision oncology offerings.

Conclusion

Exact Sciences shares were relatively calm on Friday on Nasdaq, even as the stock trades close to its 52-week high after a notable recovery from last year’s low, keeping investor attention on execution rather than short-term price swings.

The current valuation framework, which leans more on growth and cash-flow expectations than on conventional earnings metrics, underlines how closely the market is watching future test adoption, reimbursement trends and margin development at the Madison-based diagnostics specialist.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.